vaccine data News
-
Updated Data on Covid-19 Vaccine Based on Abera’s Technology Shows Neutralizing Antibodies Against Delta Version of the Virus
As previously announced, the vaccine platform developed by Abera Bioscience AB (“Abera” or “the Company”) has been used in a collaboration between researchers at Johns Hopkins University School of Medicine (Baltimore, USA) and Vrije Universiteit (Amsterdam, the Netherlands) to produce and test a novel, nasal SARS-CoV-2 vaccine candidate. Previously published data have now ...
-
Virometix Announces Publication of Key Non-Clinical Proof-ofConcept Data in Two High Quality Peer-Reviewed Journals
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases and cancer conditions, today announces publication of key non-clinical proof-of-concept data on its lead vaccine candidate V-306 in two high quality peer-reviewed journals. The data confirm the potential of V-306 for ...
By Virometix AG
-
Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose
? Meissa’s intranasal recombinant live attenuated COVID-19 vaccine, MV-014-212, induced mucosal as well as systemic antibodies against SARS-CoV-2 and two variants of concern ? MV-014-212 was built on the company’s AttenuBlock platform and is designed to be appropriately attenuated, genetically stable, and optimized to drive robust, broad, and durable immunity ? Data will be ...
-
New Data Suggest COVAXIN (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination
Level of vaccine-induced spike and nucleoprotein antibodies titers demonstrated to be comparable to that following natural infection Immune memory against conserved nucleoprotein may provide an added advantage over spike-only responses Memory T and B cells persisted for at least 6 months post vaccination Data suggest COVAXIN™ (BBV152) may provide protection against current and future ...
By Ocugen, Inc.
-
Groundbreaking new methodology published in Nature Medicine uncovers the missing numbers to the only clock that really matters in the body – your immune age
There is the age you say you are – which is not always accurate but always medically irrelevant. There is your chronological age – which is accurate but ignores inter-person variation. And then there is your immune age – the key determinant of future health and response to disease and treatment – quantified now for the first time, creating a potential paradigm shift ...
By CytoReason
-
Lumen Bioscience Announces Publication in NPJ Vaccines of Preclinical Data Demonstrating Needle Free, Spirulina-produced Vaccination Offering Protection Against Malaria
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced the publication of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner ...
-
Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data from COVAXIN (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS
COVAXIN™ whole virus inactivated vaccine generated broad antibody response comparable to those seen in a large phase 3 trial in adults 18+ Adverse events were primarily mild, and no serious adverse events (SAEs) were noted Immunobridging trial demonstrated safety, reactogenicity and immunogenicity of COVAXIN™ in children from 2 years old and up No cases of myocarditis or blood ...
By Ocugen, Inc.
-
Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children
· No vaccine is currently approved to protect against respiratory syncytial virus (RSV) · RSV is the leading cause of infant hospitalization in the United States and is considered the “missing” pediatric vaccine · Previous clinical data in seropositive adult and pediatric participants showed MV-012-968 was well-tolerated, appropriately attenuated, and stimulated ...
-
Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr
Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the third quarter ended December 31, 2021. Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, “Biocon’s consolidated Q3FY22 revenues grew by 18% YoY to Rs 2,223 Crore, driven by a strong performance ...
By Biocon
-
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3 study (PROTECT) of the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, were presented in an oral presentation at The ...
-
AKCP Develops COVID-19 Vaccine Delivery Monitoring
AKCP Coronavirus Vaccine Delivery Monitoring Solution The COVID-19 vaccines coming from Pfizer and Moderna both require storage and transportation at low temperatures. The Pfizer vaccine at -70°C +/- 10°C whereas Moderna requires -20°C. Both can be transferred to standard medical refrigerators for short periods of time. The latest COVID-19 vaccine to be announced from AstraZeneca ...
By AKCP
-
BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine
BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine candidate. BW-1010 combines BlueWillow’s patented technology, a novel oil-in-water emulsion platform that efficiently presents antigens to the ...
-
COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety
Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold across Alpha, Beta, Delta and Delta Plus variants) in neutralizing titers compared to baseline at six months Persistence of memory B and T cell immune responses at six months post second dose Pronounced SARS-CoV-2-specific T cell response to COVAXIN™ before and ...
By Ocugen, Inc.
-
Calviri Completes Enrollment of 800 Dogs in a Preventative Cancer Vaccine Trial
The double-blinded trial is testing Calviri’s vaccine aimed at broadly preventing cancers in dogs. The VACCS just completed year three of the planned five year trial. It is being conducted at three leading canine oncology centers – the Flint Animal Cancer Center at Colorado State University, the School of Veterinary Medicine at University of Wisconsin-Madison and the University of ...
By Calviri
-
Ziphius Vaccines and Ghent University Publish Promising Data from self-amplifying RNA Platform in Molecular Therapy
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, today announced that preclinical data from ZIP1642, its COVID-19 vaccine candidate, was published in the renowned scientific journal Molecular Therapy. The paper entitled ...
-
INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana. The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute ...
-
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting long-term durability of immune response data following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine has been accepted for oral presentation at The International Liver ...
-
Preventive Cancer Vaccine Trial Releases Two-Year Safety Evaluation
The Vaccine Against Canine Cancer Study (VACCS) trial (www.vaccs.org) reported its formal two-year evaluation of the safety of a vaccine to prevent cancer in healthy dogs. The largest interventional trial in dogs, it is sponsored by the Open Philanthropy Project, with additional support from Calviri, Inc., a biotech spinout from Arizona State University. The VACCS trial intends to enroll up to ...
By Calviri
-
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector therapy induces greater immune response than single-vector therapy in preclinical setting and translates into significant reduction of viral load HOOKIPA Pharma Inc. (NASDAQ: HOOK, ...
-
Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimicsTM vaccine, EO2463, in non-Hodgkin lymphoma
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine • EO2463 combines four microbiome-peptides of B lymphocytes-specific lineage markers designed to induce the full depletion of malignant B lymphocytes ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut ...
By Enterome
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you